Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) Return on Equity (2016 - 2025)

Historic Return on Equity for Heron Therapeutics (HRTX) over the last 13 years, with Q3 2025 value amounting to 0.26%.

  • Heron Therapeutics' Return on Equity fell 9200.0% to 0.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.26%, marking a year-over-year decrease of 9200.0%. This contributed to the annual value of 0.41% for FY2024, which is 104800.0% down from last year.
  • As of Q3 2025, Heron Therapeutics' Return on Equity stood at 0.26%, which was down 9200.0% from 0.04% recorded in Q2 2025.
  • Heron Therapeutics' 5-year Return on Equity high stood at 5.43% for Q2 2023, and its period low was 582.18% during Q3 2022.
  • Moreover, its 5-year median value for Return on Equity was 0.26% (2025), whereas its average is 48.24%.
  • Per our database at Business Quant, Heron Therapeutics' Return on Equity plummeted by -5805700bps in 2022 and then skyrocketed by 5857900bps in 2023.
  • Quarter analysis of 5 years shows Heron Therapeutics' Return on Equity stood at 2.22% in 2021, then plummeted by -337bps to 9.7% in 2022, then soared by 137bps to 3.58% in 2023, then tumbled by -91bps to 0.31% in 2024, then crashed by -182bps to 0.26% in 2025.
  • Its Return on Equity was 0.26% in Q3 2025, compared to 0.04% in Q2 2025 and 0.12% in Q1 2025.